



(51) International Patent Classification:

A61P 7/00 (2006.01) A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/IB2021/050464

(22) International Filing Date:

21 January 2021 (21.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/965,688 24 January 2020 (24.01.2020) US

63/104,213 22 October 2020 (22.10.2020) US

63/121,467 04 December 2020 (04.12.2020) US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street, New York, New York 10017 (US).(72) Inventors: **APGAR, James Reasoner**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **BOW-LEY, Sheryl Rubio**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **ELWELL, Joanne Elizabeth-Ayriss**; c/o Pfizer Inc., 610 Main Street, Cam-bridge, Massachusetts 02139 (US). **LIN, Laura**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **NARULA, Jatin**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PARNG, Chuen-lei**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PITTMAN, Debra Denene**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **RAKHE, Swapnil**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **YU, Chihyi Vincent**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).(74) Agent: **ZIELINSKI, Bryan C.** et al.; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE


Neutralization of HL-60 Adhesion to CHO-human E-selectin Cells
Static Assay

FIG. 7

(57) Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

